Romidepsin for cutaneous T-cell lymphoma.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Cutaneous T-cell lymphomas (CTCL) are rare cancers, with mycosis fungoides being the most common type and Sezary syndrome its leukemic variant.
• Current treatments for advanced CTCL, including bexarotene, IFN-α, and chemotherapy, often lead to inevitable relapses.
• Histone deacetylase (HDAC) inhibitors represent a promising epigenetic modification strategy for cancer therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous romidepsin for patients with relapsed or refractory CTCL.
• To assess the potential of romidepsin as a new therapeutic option in the armamentarium against CTCL.

Main Methods:

• The study was based on two large Phase II clinical trials.
• Romidepsin was administered intravenously to patients with relapsed/refractory CTCL.

Main Results:

• Intravenous romidepsin received US FDA approval for relapsed/refractory CTCL.
• Romidepsin demonstrated the potential for prolonged clinical responses in a subset of patients.
• The drug exhibited a tolerable side-effect profile.

Conclusions:

• Romidepsin is an effective and well-tolerated treatment for patients with relapsed/refractory CTCL.
• This HDAC inhibitor offers a valuable new therapeutic avenue for managing advanced CTCL.
• The approval of romidepsin provides a much-needed option for patients facing inevitable relapses with conventional therapies.